Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million

Galecto, Inc. (NASDAQ: GLTO), a Boston-based biopharmaceutical company specializing in innovative therapies for blood cancers, has announced the successful closure of its underwritten public offering, raising approximately $316.3 million in gross proceeds. The offering comprised 16,644,737 shares of common stock, which included the complete exercise of the underwriters' option to acquire an additional 2,171,052 shares. Shares were sold at a public offering price of $19.00 each.

The offering involved notable financial institutions as joint book-running managers, including Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities. The offering was facilitated through an automatically effective shelf registration statement filed with the Securities and Exchange Commission (SEC) on February 10, 2026.

Investors seeking details about the offering can find the final prospectus supplement and the related prospectus on the SEC's website or can request copies from the listed underwriters. It is crucial to note that this press release does not constitute an offer or solicitation for the purchase or sale of securities in jurisdictions where such actions would be illegal prior to proper registration or qualification under securities laws.

Galecto is advancing its clinical-stage pipeline aimed at revolutionizing the treatment landscape for hematological cancers. Its portfolio includes a unique candidate targeting mutant calreticulin-driven myeloproliferative neoplasms and GB3226, a pioneering dual inhibitor aimed at various genetic forms of acute myeloid leukemia. The company’s commitment to developing novel therapeutics positions it as a significant player in the evolving landscape of cancer treatment, fulfilling a crucial need for effective therapies in challenging medical conditions.

Galecto, Inc.'s recent public offering, which raised approximately $316.3 million, presents a pivotal moment for the company and its investors. The raised capital, largely aimed at bolstering its clinical pipeline targeting blood cancers, signals a commitment to advancing innovative therapies in a competitive market. The successful completion of this offering, including the full exercise of the underwriters' option, reflects strong institutional demand and confidence in Galecto’s prospects.

Investors should view this development with cautious optimism. The biopharmaceutical sector is characterized by high volatility, driven by factors such as clinical trial outcomes, regulatory approvals, and evolving competitive landscapes. Galecto’s unique focus on mutant calreticulin-driven myeloproliferative neoplasms and other hematological cancers positions it well in a niche market with significant unmet needs. If the company's ongoing clinical trials for products like GB3226 yield positive results, the potential for long-term returns could be substantial.

However, potential investors should remain aware of inherent risks. The market can react sharply to setbacks in clinical advancements, which underscores the importance of monitoring the company’s progress closely. Additionally, the dilution of shares as a result of the equity offering could impact short-term stock performance.

In strategic terms, investors may want to consider a phased approach to investment—establishing a position now while readying to reassess after upcoming milestones or data releases. Engaging actively with Galecto’s pipeline developments, investor briefings, and clinical trial disclosures will be crucial for making informed decisions.

Overall, while there is cautious optimism regarding Galecto's future, it’s vital for investors to balance the potential rewards against the pipeline's inherent risks, staying attuned to market dynamics and company performance.